The Diagnostic Automation Influenza B IgA Antibody ELISA Test Kit has been designed for the detection and quantitative determination of specific IgA antibodies against Influenza B in human serum and plasma. Further applications in other body fluids are possible and can be requested from the Technical Service of Diagnostic Automation Inc.





Materials Provided with Influenza B IgA ELISA Kit:
1. Influenza B antigen coated Microplate Strips: 12 strips with 8 breakable wells,
coated with Influenza B antigen (Current vaccine, strain Harbin)
2. Influenza B IgA ELISA kit Calibrator A (Negative Control)
3. Influenza B IgA ELISA kit Calibrator B (Cut-Off Standard)
4. Influenza B IgA ELISA Test Calibrator C (Weak Positive Control)
5. Influenza B IgA ELISA Test Calibrator D (Positive Control)
6. Influenza B IgA EIA kit Enzyme Conjugate
anti-human-IgA-HRP (rabbit), in protein-containing buffer solution
7. Substrate TMB
8. Influenza B IgA Kit Stop Solution
9. Sample Diluent
10. Washing Buffer: 10x concentrate
11. Plastic Foils
12. Plastic Bag

Materials & Instrumentation required not included:
1. Reagent tubes for the serum dilution
2. Bidistilled water
3. Precision pipettes
4. EIA Kit Microplate Washer
5. EIA Kit Microplate Reader at 450 nm wavelength





Influenza B IgA ELISA Kit Background Information
The influenza infection is an acute feverish virus infection, which principally leads to an illness of the respiratory tract and appears as an epidemic or pandemic. The infection mostly results from a droplet infection. The virus spreads from the mucous membrane of the upper respiratory to the whole bronchial tract. There the virus and its toxin can lead to a serious inflammation of the bronchial mucosa and a damage of the vessels. After an incubation time of 1 to 3 days the symptoms appear suddenly: Followed by a fast increase of temperature, often accompanied by shivering, the catarrhal leading symptom appears, which contribute to the clinical course beside painful dry cough, tracheitis, laryngitis and frequently a rhinitis and conjunctivitis. The Influenza viruses form a virus group with principally similar morphological, chemical and biological features. The determination of the Influenza type (A, B, and C) gives both the clinician and epidemiologist important indications for further actions. Thus Influenza B often leads to a serious clinical course and an epidemic spread of the virus. Similarly, during an Influenza A epidemic, the epidemiological importance and derived measures for the protection of the individual and population primarily stand in the foreground together with the severity of the clinical symptoms.





Influenza B IgA ELISA Test Principle
The Diagnostic Automation Inc. Influenza B IgA antibody test kit is based on the principle of the enzyme immunoassay (EIA). Influenza B antigen is bound on the surface of the microtiter strips. Diluted patient serum or ready-to-use standards are pipetted into the wells of the microtiter plate. A binding between the IgA antibodies of the serum and the immobilized Influenza B antigen takes place. After one hour incubation at room temperature, the plate is rinsed with diluted wash solution, in order to remove unbound material. Then ready-to-use anti-human-IgA peroxidase conjugate is added and incubated for 30 minutes. After a further washing step, the substrate (TMB) solution is pipetted and incubated for 20 minutes, inducing the development of a blue dye in the wells. The color development is terminated by the addition of a stop solution, which changes the color from blue to yellow. The resulting dye is measured spectrophotometrically at the wavelength of 450 nm. The concentration of the IgA antibodies is directly proportional to the intensity of the color.





Influenza B IgA ELISA test kit Qualitative Evaluation
The calculated absorptions for the patient sera are compared with the value for the cutoff standard. If the value of the sample is higher, there is a positive result. For a value below the cut-off standard, there is a negative result. It is recommended to define a range of +/- 20 % around the value of the cut-off as a grey zone. In such a case the repetition of the test with the same serum or with a new sample of the same patient, taken after 2-4 weeks, is recommended. Both samples should be measured in parallel in the same run.The positive control must show at least the double absorption compared with the cut-off standard.




Influenza B IgA ELISA Test Characteristic & Performances
Intra-Assay-Precision 7.3%
Inter-Assay-Precision 8.0 %
Inter-Lot-Precision 1.1 5.9 %
Analytical Sensitivity 1.38 U/ml
Recovery 94 106 %
Linearity 77 124 %
Clinical Specificity 100 %
Clinical Sensitivity 85 %
Cross-Reactivity No cross-reactivity to RSV, Adenovirus & Parainfluenza 1/2/3
Interferences No interferences to bilirubin up to 0.3 mg/ml,
hemoglobin up to 8.0 mg/ml& triglycerides up to 5.0 mg/ml




Influenza B IgA Related ELISA kits:

Influenza B IgG ELISA Kit

http://www.rapidtest.com/index.php?i=Influenza-B-IgG-ELISA-kit&id=97&cat=16

Influenza B IgM ELISA Kit

http://www.rapidtest.com/index.php?i=Influenza-B-IgM-ELISA-kit&id=98&cat=16


Diagnostic Automation Inc. also provides other Infectious Disease ELISA Kits:

http://www.rapidtest.com/index.php?product=Infectious-Disease-ELISA-kits&cat=16

For more information about these Kits or Rapid Tests, IFA Kits, CLIA Test Kits, or Serology tests, please see our website home page, or contact our Customer Service Representative at 818-591-3030.